Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Pentamidine is an antimicrobial and antiprotozoal small molecule used primarily to treat and prevent Pneumocystis pneumonia (PCP), especially in immunocompromised patients such as those with HIV/AIDS. It is also effective against other protozoal infections including African trypanosomiasis (sleeping sickness), leishmaniasis, babesiosis, and Balamuthia infections. The precise mechanism of action is not fully understood but involves interference with nuclear metabolism in susceptible organisms—specifically inhibiting the synthesis of DNA, RNA, phospholipids, and proteins. Pentamidine can be administered via inhalation or injection[1][2][3][6].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on pentamidine.